Back to Search
Start Over
Teclistamab: Mechanism of action, clinical, and translational science.
- Source :
-
CTS: Clinical & Translational Science . Jan2024, Vol. 17 Issue 1, p1-8. 8p. - Publication Year :
- 2024
-
Abstract
- Multiple myeloma (MM) remains incurable despite improvements in treatment options. B‐cell maturation antigen (BCMA) is predominantly expressed in B‐lineage cells and represents a promising new target for MM. Teclistamab (TECVAYLITM) is the first T‐cell redirecting bispecific antibody approved for patients with MM. Targeting both CD3 receptor complex on T cells and BCMA on myeloma cells, teclistamab leads to T‐cell activation and subsequent lysis of BCMA+ cells. The recommended dose of teclistamab is 1.5 mg/kg subcutaneous weekly after two step‐up doses of 0.06 and 0.3 mg/kg, which was selected after review of safety, efficacy, pharmacokinetic, and pharmacodynamic data. Exposure‐response analyses of efficacy and safety data were also used to confirm the teclistamab dose. Teclistamab resulted in a high rate of deep and durable responses (63% overall response, 45.5% complete response or better, with 22 months median duration of response) in patients with triple‐exposed relapsed/refractory MM. Common adverse reactions included cytokine release syndrome, hematologic abnormalities, and infections. Teclistamab is currently being investigated as monotherapy as well as combination therapy across different MM indications. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 17528054
- Volume :
- 17
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- CTS: Clinical & Translational Science
- Publication Type :
- Academic Journal
- Accession number :
- 175009211
- Full Text :
- https://doi.org/10.1111/cts.13717